Valuation: Allogene Therapeutics, Inc.

Market Cap 504M 451M 420M 382M 719M 48.79B 725M 5.05B 1.97B 24.82B 1.89B 1.85B 79.78B P/E 2026 *
-2.42x
P/E 2027 * -2.27x
Enterprise Value 308M 275M 257M 233M 439M 29.78B 442M 3.08B 1.2B 15.15B 1.16B 1.13B 48.69B EV / Sales 2026 *
90.6x
EV / Sales 2027 * 29.3x
Free-Float
88.97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week-10.62%
Current month-10.62%
1 month-23.12%
3 months-33.49%
6 months-45.42%
Current year+4.38%
1 week 1.42
Extreme 1.425
1.61
1 month 1.42
Extreme 1.425
1.94
Current year 1.31
Extreme 1.31
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
20.75
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 30/06/2026
Director of Finance/CFO 61 15/10/2023
Chief Tech/Sci/R&D Officer 49 27/02/2025
Director TitleAgeSince
Chairman 76 31/10/2017
Director/Board Member 66 31/05/2018
Director/Board Member 49 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Sell

Compliance Officer

-29,697 0.0086%
01/07/26 Free

Chief Executive Officer

610,720 0.1769%
18/06/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-10.62%+5.93%-51.85% 504M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.16%-2.71%+328.81%+684.04% 42.84B
-0.72%-4.05%+28.42%+29.27% 42.79B
-0.04%-0.97%+6.08%+109.73% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.03%-2.41%-9.55%-12.24% 24.05B
Average -0.02%-1.22%+48.36%+104.62% 39.48B
Weighted average by Cap. +0.58%-0.55%+55.91%+128.13%

Financials

2026 *2027 *
Net sales 3.4M 3.04M 2.83M 2.57M 4.85M 329M 4.88M 34.06M 13.31M 167M 12.76M 12.49M 538M 12.09M 10.8M 10.07M 9.15M 17.23M 1.17B 17.36M 121M 47.3M 595M 45.37M 44.39M 1.91B
Net income -185M -165M -154M -140M -264M -17.91B -266M -1.85B -725M -9.11B -695M -680M -29.28B -220M -196M -183M -166M -313M -21.27B -316M -2.2B -860M -10.82B -825M -807M -34.77B
Net Debt -197M -176M -164M -149M -280M -19.01B -282M -1.97B -769M -9.67B -738M -722M -31.08B -150M -134M -125M -114M -214M -14.53B -216M -1.5B -588M -7.39B -564M -552M -23.75B
Projected Income Statement - Annual - Allogene Therapeutics, Inc.
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
07/10/26 US$1.430 -2.05% 2,697,201
06/10/26 US$1.460 -2.67% 4,659,678
05/10/26 US$1.500 0.00% 4,443,265
02/10/26 US$1.500 -2.60% 4,656,621
01/10/26 US$1.540 -3.75% 4,606,898
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Allogene Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.460USD
Average target price
9.000USD
Spread / Average Target
+516.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Allogene Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALLO Stock